治疗性多肽及其脂基纳米颗粒的递送。

IF 1.6 Q2 MEDICINE, GENERAL & INTERNAL
Tzu Chi Medical Journal Pub Date : 2025-05-02 eCollection Date: 2025-07-01 DOI:10.4103/tcmj.tcmj_321_24
Jui-Hung Yen, Chun-Chun Chang, Tien-Yuan Wu, Chin-Hao Yang, Hao-Jen Hsu, Je-Wen Liou
{"title":"治疗性多肽及其脂基纳米颗粒的递送。","authors":"Jui-Hung Yen, Chun-Chun Chang, Tien-Yuan Wu, Chin-Hao Yang, Hao-Jen Hsu, Je-Wen Liou","doi":"10.4103/tcmj.tcmj_321_24","DOIUrl":null,"url":null,"abstract":"<p><p>Therapeutic peptides have become an intensively anticipated research field for novel drug discovery and design owing to their high specificity, efficacy, and biocompatibility. The advances in computer technology and structural biology, together with the invention of chemical peptide synthesis methods, have led to tremendous progress in this research field. Over the years, more than 100 peptide-based therapeutics have been approved for clinical use, and many others are currently under clinical trials. However, the <i>in vivo</i> application of therapeutic peptides is hindered by intrinsic disadvantages of peptides, such as poor stability against enzymatic degradations, short <i>in vivo</i> half-life, and low oral bioavailability. Therefore, strategies for efficiently protecting the peptides inside the body and facilitating the delivery of peptides to their targets are required. Lipid-based nanoparticles are considered a versatile class of carriers for drug delivery. Their biocompatibility, biodegradability, and ability to interact with biological membranes make them ideal platforms for <i>in vivo</i> delivery of peptides. Here, by leveraging examples, we aim to provide a comprehensive review of the current status of therapeutic peptide developments and lipid-based nanoparticles as drug carriers. Recent attempts to utilize lipid-based nanoparticles as platforms for the oral delivery of therapeutic peptides are also discussed.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"37 3","pages":"223-234"},"PeriodicalIF":1.6000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306875/pdf/","citationCount":"0","resultStr":"{\"title\":\"Therapeutic peptides and their delivery using lipid-based nanoparticles.\",\"authors\":\"Jui-Hung Yen, Chun-Chun Chang, Tien-Yuan Wu, Chin-Hao Yang, Hao-Jen Hsu, Je-Wen Liou\",\"doi\":\"10.4103/tcmj.tcmj_321_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Therapeutic peptides have become an intensively anticipated research field for novel drug discovery and design owing to their high specificity, efficacy, and biocompatibility. The advances in computer technology and structural biology, together with the invention of chemical peptide synthesis methods, have led to tremendous progress in this research field. Over the years, more than 100 peptide-based therapeutics have been approved for clinical use, and many others are currently under clinical trials. However, the <i>in vivo</i> application of therapeutic peptides is hindered by intrinsic disadvantages of peptides, such as poor stability against enzymatic degradations, short <i>in vivo</i> half-life, and low oral bioavailability. Therefore, strategies for efficiently protecting the peptides inside the body and facilitating the delivery of peptides to their targets are required. Lipid-based nanoparticles are considered a versatile class of carriers for drug delivery. Their biocompatibility, biodegradability, and ability to interact with biological membranes make them ideal platforms for <i>in vivo</i> delivery of peptides. Here, by leveraging examples, we aim to provide a comprehensive review of the current status of therapeutic peptide developments and lipid-based nanoparticles as drug carriers. Recent attempts to utilize lipid-based nanoparticles as platforms for the oral delivery of therapeutic peptides are also discussed.</p>\",\"PeriodicalId\":45873,\"journal\":{\"name\":\"Tzu Chi Medical Journal\",\"volume\":\"37 3\",\"pages\":\"223-234\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-05-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306875/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tzu Chi Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/tcmj.tcmj_321_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tzu Chi Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/tcmj.tcmj_321_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

治疗肽由于其高特异性、高效性和生物相容性,已成为新药开发和设计的一个备受期待的研究领域。计算机技术和结构生物学的进步,以及化学多肽合成方法的发明,使这一研究领域取得了巨大的进步。多年来,超过100种基于肽的疗法已被批准用于临床应用,还有许多其他疗法目前正在临床试验中。然而,治疗性多肽的体内应用受到多肽固有缺点的阻碍,如抗酶降解稳定性差,体内半衰期短,口服生物利用度低。因此,需要有效地保护体内肽并促进肽向靶点的传递的策略。脂基纳米颗粒被认为是一种多用途的药物输送载体。它们的生物相容性、生物可降解性以及与生物膜相互作用的能力使它们成为体内递送多肽的理想平台。在这里,通过举例,我们的目的是提供一个全面的综述,目前的治疗肽的发展和基于脂质纳米颗粒作为药物载体。最近的尝试利用基于脂质的纳米颗粒作为平台的口服递送治疗肽也进行了讨论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Therapeutic peptides and their delivery using lipid-based nanoparticles.

Therapeutic peptides and their delivery using lipid-based nanoparticles.

Therapeutic peptides and their delivery using lipid-based nanoparticles.

Therapeutic peptides and their delivery using lipid-based nanoparticles.

Therapeutic peptides have become an intensively anticipated research field for novel drug discovery and design owing to their high specificity, efficacy, and biocompatibility. The advances in computer technology and structural biology, together with the invention of chemical peptide synthesis methods, have led to tremendous progress in this research field. Over the years, more than 100 peptide-based therapeutics have been approved for clinical use, and many others are currently under clinical trials. However, the in vivo application of therapeutic peptides is hindered by intrinsic disadvantages of peptides, such as poor stability against enzymatic degradations, short in vivo half-life, and low oral bioavailability. Therefore, strategies for efficiently protecting the peptides inside the body and facilitating the delivery of peptides to their targets are required. Lipid-based nanoparticles are considered a versatile class of carriers for drug delivery. Their biocompatibility, biodegradability, and ability to interact with biological membranes make them ideal platforms for in vivo delivery of peptides. Here, by leveraging examples, we aim to provide a comprehensive review of the current status of therapeutic peptide developments and lipid-based nanoparticles as drug carriers. Recent attempts to utilize lipid-based nanoparticles as platforms for the oral delivery of therapeutic peptides are also discussed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Tzu Chi Medical Journal
Tzu Chi Medical Journal MEDICINE, GENERAL & INTERNAL-
CiteScore
3.40
自引率
0.00%
发文量
44
审稿时长
13 weeks
期刊介绍: The Tzu Chi Medical Journal is the peer-reviewed publication of the Buddhist Compassion Relief Tzu Chi Foundation, and includes original research papers on clinical medicine and basic science, case reports, clinical pathological pages, and review articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信